Growth hormone peptide blend

Sermorelin + Ipamorelin

Sermorelin + Ipamorelin: the app lists a half-life of 0.5 hours, while published figures are about 4.3 minutes for sermorelin and 2 hours for ipamorelin.1,2

Emerging evidence (the app's grade, not a conclusion of the sources)Get the app

Level after one dose

Sermorelin + Ipamorelin after one dose: 50% at ~0.5 h, 25% at 1 h, 12.5% at 1.5 h.

Drawn from the half-life in the app's model, ~0.5 h. The model's figures

1

Overview

The app lists Sermorelin + Ipamorelin as a pre-mixed blend of two growth hormone peptides, with 5 mg of sermorelin and 5 mg of ipamorelin per vial. Sermorelin is described by Prakash and Goa (Adis International, BioDrugs, 1999) as "a 29 amino acid analogue of human growth hormone-releasing hormone (GHRH)".3 Ipamorelin is described by Raun and colleagues (Novo Nordisk, European Journal of Endocrinology, 1998) as "a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2)" that acts through a growth hormone releasing peptide (GHRP)-like receptor.4

No study of the sermorelin and ipamorelin blend itself in people was identified in PubMed or ClinicalTrials.gov. The human evidence below therefore belongs to each component separately, and a result in one component is not a result for the blend. The app grades the evidence for the blend as emerging.

The app's notes describe two "complementary pathways" (a GHRH analog and a ghrelin-receptor agonist) that together amplify pulsatile growth hormone release. Nothing cited here measured that combined effect for this blend. Prakash and Goa write that "Intravenous and subcutaneous sermorelin specifically stimulate growth hormone secretion from the anterior pituitary".3 Walker, in a 2006 editorial in Clinical Interventions in Aging, lists among sermorelin's features that "Effects are regulated by negative feedback involving the inhibitory neurohormone, somatostatin".5 That editorial is by an author affiliated with the International Society for Applied Research in Aging, which states that it "will be providing sermorelin free of cost on a competitive basis to practitioners willing to study its effects".5 For ipamorelin, Raun and colleagues report from animal work that "ipamorelin, like GHRP-6, stimulates GH release via a GHRP-like receptor".4 In conscious swine, "None of the GH secretagogues tested affected FSH, LH, PRL or TSH plasma levels", and "ipamorelin did not release ACTH or cortisol in levels significantly different from those observed following GHRH stimulation".4 The FDA briefing document on ipamorelin likewise states that it stimulates growth hormone release "without major effects on adrenocorticotropic hormone or cortisol levels".6

Deeper analysis: Raun and colleagues, ipamorelin pharmacology (1998)

Raun and colleagues, from the Department of GH Biology at Novo Nordisk in Denmark, tested ipamorelin in rat pituitary cells, anaesthetised rats and conscious swine, not in people.4 In rat pituitary cells the reported potency values were 1.3+/-0.4 nmol/l for ipamorelin and 2.2+/-0.3 nmol/l for GHRP-6, with "a potency and efficacy similar to GHRP-6".4 In swine, GHRP-6 and GHRP-2 "resulted in increased plasma levels of ACTH and cortisol", which ipamorelin did not do, even "at doses more than 200-fold higher than the ED50 for GH release".4 The authors conclude that the specificity "makes this compound a very interesting candidate for future clinical development".4 The saved record gives no funding statement and no stated limitations, and the work did not include any human data.4

3

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~0.5 h
Bioavailability
95%
Typical dose
200–300 mcg
Route
SubQ
Time to peak
~0.3 h

The table sets the app's figures beside what the sources report; the sources give figures for each peptide, not for the blend.

Table 3.1Half-life and pharmacokinetics4 rows
ParameterApp's figureReported in the sources
Half-life~0.5 h (30 minutes)Sermorelin: a disappearance half-time of about 4.3 ± 1.4 minutes, as tabulated in a 2026 review. Ipamorelin: a terminal half-life of 2 hours in healthy men, and "t½ ~ 2h" in the same review.1,2
Bioavailability95%None of the sources cited here gives a subcutaneous bioavailability for sermorelin or ipamorelin.
Time to peak~0.3 h (18 minutes)Ipamorelin: growth hormone, not the drug, peaked at 0.67 hours after a 15-minute infusion; the review gives growth hormone peaks of about 40 to 60 minutes after administration in a phase I study.2,1
Clearance and distributionNot listedIpamorelin: clearance of 0.078 L/h/kg and a volume of distribution at steady state of 0.22 L/kg.2

Gobburu and colleagues gave 5 infusion rates of ipamorelin to eight healthy male subjects at each dose level, and reported that the "PK parameters showed dose-proportionality".2 The FDA briefing document describes growth hormone concentrations that "declined to very low concentration at all doses by 6 hours".6 The sermorelin figure is a review's tabulated value for sermorelin given intravenously or subcutaneously, and the 2-hour ipamorelin figure comes from intravenous infusions, so neither is a subcutaneous blend measurement.1,2

4

Human studies

No controlled trial of the blend was identified. The rows below are component studies, and none used the blend.

Table 4.1Human studies4 rows
Study and yearDesignPeopleDose and lengthMain result
Gobburu and colleagues, Pharmaceutical Research 1999 (ipamorelin)2Dose-escalation pharmacokinetic and pharmacodynamic trial; listed as a randomized controlled trialEight healthy male subjects at each of 5 dose levels4.21 to 140.45 nmol/kg intravenously over 15 minutesTerminal half-life 2 hours; single episode of GH release peaking at 0.67 hours; SC50 214 nmol/L
Beck and colleagues, International Journal of Colorectal Disease 2014 (ipamorelin)7Multicenter, double-blind, placebo-controlled phase 2 trial117 adults enrolled after small or large bowel resection; 114 analysed0.03 mg/kg intravenously twice daily from postoperative day 1 to 7 or dischargeMedian time to first tolerated meal 25.3 h with ipamorelin and 32.6 h with placebo (p = 0.15)
Helsinn registry entry NCT01280344 (ipamorelin)9Phase 2, randomized, quadruple-masked, placebo-controlled, dose-finding320 enrolled, ages 18 to 85, after open partial bowel resection0.03 mg/kg twice daily, 0.06 mg/kg twice daily or 0.06 mg/kg three times daily intravenously, against placeboStatus COMPLETED; the entry as saved holds no results
Prakash and Goa, BioDrugs 1999 (sermorelin review)3Review of sermorelin in diagnosis and treatmentChildren with idiopathic growth hormone deficiency30 microg/kg bodyweight subcutaneously at bedtime, once daily; 12 months, with data in a few children to 36 monthsLimited data: significant height velocity increases were sustained over 12 months; with 30 microg/kg per day given as continuous infusion or 3 divided doses, increases were less than with once-daily subcutaneous somatropin

Deeper analysis: Beck and colleagues, ipamorelin in postoperative ileus (2014)

Beck and colleagues ran a multicenter, double-blind, placebo-controlled phase 2 trial of intravenous ipamorelin in adults undergoing small and large bowel resection, registered as NCT00672074.7,8 The key efficacy endpoint was "time from first dose of study drug to tolerance of a standardized solid meal".7 The median was 25.3 hours with ipamorelin and 32.6 hours with placebo (p = 0.15), and the authors report "no significant differences between ipamorelin and placebo in the key and secondary efficacy analyses".7 Any treatment-emergent adverse event occurred in 87.5% of the ipamorelin group and 94.8% of the placebo group, and the authors conclude that 0.03 mg/kg twice daily for up to 7 days "was well tolerated".7 The FDA's 2024 briefing document reviewed the same trial and reports hypokalemia in 12.5% on ipamorelin against 3.4% on placebo, insomnia in 10.7% against 5.2%, and hyperglycemia at discharge in 14.3% against 8.6%.6 It reports serious adverse events in 10 subjects (17.9%) on ipamorelin and 9 (15.5%) on placebo, discontinuations in three subjects in each group, and two fatal serious adverse events among subjects given ipamorelin, both after bowel resection for colon cancer complicated by anastomotic leak.6 The FDA states "it is unclear whether the deaths reported in the above study were related to ipamorelin".6 The authors' stated limitation is that "This proof of concept study was small and enrolled patients with a broad range of underlying conditions".7 The registry entry names Helsinn Therapeutics (U.S.), Inc as lead sponsor, with 117 participants enrolled and masking of participant, care provider, investigator and outcomes assessor.8 The saved PubMed record lists the first author at the Department of Colon and Rectal Surgery, Ochsner Clinic Foundation, and states no author ties to the sponsor.7 The PubMed record carries the publication type "Research Support, Non-U.S. Gov't" and gives no funding statement, while the registry entry names Helsinn Therapeutics (U.S.), Inc as lead sponsor.7,8 The trial studied ipamorelin intravenously in surgical patients and says nothing about subcutaneous use, growth hormone or IGF-1 in healthy people, or the blend.7 A second phase 2 dose-finding trial (NCT01280344, 320 participants) compared three intravenous regimens with placebo; its registry entry lists status COMPLETED, and the entry as saved holds no results.9

Deeper analysis: Gobburu and colleagues, ipamorelin in healthy volunteers (1999)

Gobburu and colleagues measured ipamorelin and growth hormone concentrations in healthy men after 15-minute intravenous infusions at 5 dose levels (4.21 to 140.45 nmol/kg) with eight men per level.2 The FDA briefing document describes the same study as enrolling 48 subjects, with 6 healthy men per group receiving ipamorelin and 2 per group receiving placebo, and states that the lowest dose group and the placebo groups were not included in the PK/PD analysis because of negligible GH levels.6 They report a "single episode of GH release with a peak at 0.67 hours and an exponential decline to negligible GH concentration at all doses".2 The model gave a concentration for half-maximal stimulation (SC50) of 214 nmol/L and a maximal GH production rate of 694 mIU/L/h, and "The inter-individual variability of the PD parameters was larger than that of the PK parameters".2 The FDA briefing document notes that the paper "did not state that" adverse events occurred, that the trial was in "healthy subjects with intact hypothalamic-pituitary axis", and that people with growth hormone deficiency "may not be expected to show the same PK/PD profiles".6 The saved PubMed record names the first author at the State University of New York at Buffalo, lists no funding statement, and states no limitations.2

Deeper analysis: sermorelin evidence (Prakash and Goa 1999; Walker 2006)

Prakash and Goa reviewed sermorelin in children with idiopathic growth hormone deficiency and write that "Limited data indicate that once daily subcutaneous sermorelin 30 microg/kg bodyweight given at bedtime is effective in treating some prepubertal children".3 Their review states that "The effect of long term treatment with once daily subcutaneous sermorelin 30 microg/kg bodyweight on final adult height is yet to be determined", that the effects of the recommended dosage "have not been directly compared with those of somatropin", and that increases with 30 microg/kg per day given as continuous infusion or 3 divided doses were less than with once-daily subcutaneous somatropin.3 Hormone responses to a single intravenous dose of 1 microg/kg were described as appearing to be a "rapid and relatively specific test for the diagnosis of growth hormone deficiency".3 These data come from children with growth hormone deficiency, and the saved record gives no funding statement.3 Walker's editorial states that sermorelin "could not compete with rhGH and was withdrawn as a therapeutic entity by the manufacturer" as a growth-promoting agent in children.5 The 2026 review by Dominikowski and colleagues (Frontiers in Endocrinology, no external funding, no declared conflicts) says that in off-label use "clinically meaningful benefits in healthy individuals remain uncertain because the human evidence base is limited and largely indirect".1 The same review states of ipamorelin used with CJC-1295 that "controlled clinical evidence supporting synergy or meaningful body-composition outcomes in healthy individuals remains limited".1

No label for the blend or for sermorelin was identified, and a DailyMed search for "sermorelin" returned no labels. The FDA briefing document states that for ipamorelin free base and acetate "neither is a component of an FDA-approved drug".6

Table 5.1Doses reported in studies and on labels7 rows
Compound and contextDose and routeReference
The app's figure for the blend200–300 mcg subcutaneously; vial of 5 mg sermorelin and 5 mg ipamorelinThe app
Ipamorelin, healthy men, single dose, 8 per level (Gobburu 1999)4.21 to 140.45 nmol/kg intravenously over 15 minutes2
Ipamorelin, adults after bowel resection, placebo-controlled, 117 enrolled (Beck 2014)0.03 mg/kg intravenously twice daily, postoperative day 1 to 7 or discharge7
Ipamorelin, adults after bowel resection, dose-finding against placebo, 320 enrolled (NCT01280344)0.03 mg/kg twice daily, 0.06 mg/kg twice daily, 0.06 mg/kg three times daily, intravenously9
Sermorelin, prepubertal children with idiopathic growth hormone deficiency (review)30 microg/kg bodyweight subcutaneously once daily at bedtime3
Sermorelin, diagnostic test (review)1 microg/kg bodyweight intravenously as a single dose3
Sermorelin and ipamorelin, self-reported on online bodybuilding forums, as tabulated by a 2026 reviewSermorelin 200–300 µg subcutaneously once daily; ipamorelin 200-300 µg subcutaneously 2 or 3 injections a day1

The review that tabulated the online figures states that those patterns "are not evidence-based treatment strategies".1

For ipamorelin, the adverse event rates from the postoperative ileus trial are given above: 87.5% against 94.8% for any event, with higher rates of hypokalemia, insomnia and hyperglycemia at discharge on ipamorelin, and two fatal serious adverse events in that group, in surgical patients receiving it intravenously.7,6 For sermorelin in children, Prakash and Goa write that "Transient facial flushing and pain at injection site were the most commonly reported adverse events".3 The 2026 review lists for sermorelin "Injection-site pain; short-term flushing, nausea, dizziness, headache; rare allergic reaction; transient PRL rise reported (small/rapid)", and states "No long term safety data available".1 For the combination, the FDA briefing document describes one FAERS report of a 46-year-old man who self-administered a compounded ipamorelin and sermorelin product by subcutaneous injection for 2 months and had arthralgia with left elbow joint pain.6 The same FAERS search retrieved two reports of non-serious adverse events in total; the other was a 32-year-old man who used a compounded single-ingredient ipamorelin nasal spray and had increased lacrimation and headache assumed to be related to a product quality issue, and in the report above the pain did not resolve after stopping the injections but became less severe.6 The FDA states that "it is not possible to assess a potential relationship between ipamorelin specifically and the reported adverse event", and that it "cannot make definitive conclusions regarding the safety" of ipamorelin from such reports.6 The FDA also states that it "cannot rule out the potential for immunogenicity associated with these impurities" for ipamorelin.6

The app lists IGF-1, blood glucose and insulin as markers to monitor. The 2026 review tabulates sermorelin as producing "secondary ↑ IGF-1" after increased endogenous pulsatile growth hormone secretion.1 In the ipamorelin ileus trial, the FDA's review reports hyperglycemia at discharge in 14.3% on ipamorelin and 8.6% on placebo.6 None of the sources cited here reports IGF-1, glucose or insulin values for the blend.

The World Anti-Doping Agency's 2026 Prohibited List places both peptides in class S2, section S2.2.4 on growth hormone releasing factors.10 The class is headed "PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)", and the list states that "All prohibited substances in this class are non-Specified Substances".10 The 2026 review states that sermorelin acetate was "previously FDA-approved" and marketed as Geref, and that "the corresponding approvals were withdrawn effective June 18, 2009".1 It adds that "FDA subsequently determined that Geref was not withdrawn for reasons of safety or effectiveness".1 The review's table describes sermorelin as "commercially withdrawn 2008", a different year from the June 18, 2009 date given for the approvals in its text.1 For ipamorelin, the FDA's October 29, 2024 briefing document for its Pharmacy Compounding Advisory Committee states "we propose not adding ipamorelin acetate or ipamorelin (free base) to the 503A Bulks List".6 The document says the FDA "will not issue a final determination" until the committee's input has been considered, and the outcome is not in the sources cited here.6 Its stated reasons include the lack of data on physicochemical characterization, "identified safety concerns", and "lack of data to support effectiveness".6 No EMA or TGA document on either peptide is cited here.

No study of the sermorelin and ipamorelin blend in people was identified, so its effect on growth hormone, IGF-1, body composition or glucose is unmeasured in the sources cited here. One ClinicalTrials.gov entry located that mentions ipamorelin outside the ileus trials is an observational study of Special Operations Forces combat veterans (NCT07717866) that lists ipamorelin among several supplements, not as a sermorelin blend.11 Whether the two peptides together release more growth hormone than either alone has not been shown for this pair in the sources cited here. The human ipamorelin trials were in surgical patients, with intravenous dosing, and the sermorelin trials in children with growth hormone deficiency.7,3 The 2026 review's evidence summary for ipamorelin states "no long term safety data available".1 The app's bioavailability of 95% and its time to peak of about 0.3 hours have no matching figure in the sources cited here.

What is the half-life of Sermorelin + Ipamorelin?

The app lists a half-life of about 0.5 hours (30 minutes) for the blend, and the sources cited here give no half-life for the blend. The components have separate figures: about 4.3 minutes for sermorelin in a review, and 2 hours for ipamorelin in healthy men.1,2

What is the half-life of ipamorelin?

Gobburu and colleagues report a terminal half-life of 2 hours for ipamorelin after intravenous infusion in healthy men, against the app's 0.5 hours for the blend.2

What is the half-life of sermorelin?

A 2026 review tabulates a disappearance half-time of about 4.3 ± 1.4 minutes for sermorelin, against the app's 0.5 hours for the blend.1

Is Sermorelin + Ipamorelin banned by WADA?

The WADA 2026 Prohibited List names both sermorelin and ipamorelin in section S2.2.4, in a class prohibited at all times.10

Is Sermorelin + Ipamorelin FDA approved?

The FDA briefing document states that ipamorelin "neither is a component of an FDA-approved drug", and no label for the blend is cited here.6 Sermorelin acetate was FDA-approved as Geref, and its approvals were withdrawn effective June 18, 2009, which the FDA later determined was not for reasons of safety or effectiveness.1

Has Sermorelin + Ipamorelin been studied in people?

No study of the blend in people was identified in PubMed or ClinicalTrials.gov. Ipamorelin alone was studied in a phase 2 trial in 117 adults after bowel resection, which reported no significant differences from placebo in the key and secondary efficacy analyses, and a second phase 2 trial with 320 enrolled lists no results; sermorelin alone is described in a review of children with growth hormone deficiency.7,9,3

Did ipamorelin work in its postoperative ileus trial?

In the phase 2 trial by Beck and colleagues, the median time to first tolerated meal was 25.3 hours with ipamorelin and 32.6 hours with placebo (p = 0.15), which the authors report as no significant difference.7 The FDA's review of the trial reports two fatal serious adverse events in the ipamorelin group and states it is unclear whether they were related to ipamorelin.6

Does ipamorelin raise cortisol?

In conscious swine, ipamorelin did not release ACTH or cortisol in levels significantly different from those after GHRH stimulation, whereas GHRP-6 and GHRP-2 raised them.4 That result is from animals, and the sources cited here give no cortisol data for the blend in people.4

Which markers does the app list for Sermorelin + Ipamorelin?

The app lists IGF-1, blood glucose and insulin.

12

References

  1. Dominikowski A, et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol (Lausanne) 2026. PMID 42395176
  2. Gobburu JV, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res 1999. PMID 10496658
  3. Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs 1999. PMID 18031173
  4. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 1998. PMID 9849822
  5. Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging 2006. PMID 18046908
  6. US Food and Drug Administration. FDA Briefing Document, Pharmacy Compounding Advisory Committee meeting, October 29, 2024: ipamorelin-related bulk drug substances. FDA briefing document
  7. Beck DE, et al. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis 2014. PMID 25331030
  8. ClinicalTrials.gov NCT00672074. Safety and Efficacy of Ipamorelin for Management of Post-Operative Ileus. Helsinn Therapeutics (U.S.), Inc. NCT00672074
  9. ClinicalTrials.gov NCT01280344. Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function. Helsinn Therapeutics (U.S.), Inc. NCT01280344
  10. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list
  11. ClinicalTrials.gov NCT07717866. Trifecta Research Study. Axial Therapeutic Research. NCT07717866